Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381021 | 0.85 | SLC1A3 (0.53) | ALDH1A1GAAF2PRSS1PRSS2 | |
| SCHEMBL3442045 | 0.81 | CA1 (0.56) | ALDH1A1GAAF2PRSS1PRSS2 | |
| SCHEMBL27874923 | 0.81 | F2 (0.47) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4591540 | 0.79 | ALDH1A1 (0.49) | ALDH1A1GAAF2PRSS1PRSS2 | |
| SCHEMBL13278238 | 0.79 | KMT2A (0.48) | ALDH1A1GAACA1CA2CA12 | |
| SCHEMBL27749595 | 0.78 | CA1 (0.50) | F2CA1CA2CA12CA9 | |
| SCHEMBL528908 | 0.77 | ALDH1A1 (0.46) | ALDH1A1GAAF2PRSS1PRSS2 | |
| SCHEMBL26108918 | 0.77 | ALDH1A1 (0.50) | ALDH1A1GAAF2PRSS1PRSS2 | |
| Acetamide SCHEMBL538407 | 0.75 | GAA (0.73) | ALDH1A1GAAF2PRSS1PRSS2 | |
| SCHEMBL3681331 | 0.75 | CA1 (0.54) | ALDH1A1GAAF2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595620-A2 | BENZENESULFONAMIDE-COMPOUND TREATMENT OF A PATHOLOGICAL CONDITION LINKED TO AN EXCESSIVE EFFECT OF TNF | Vaxconsulting (FR) | 2013-05-29 | — | — | EP | claimed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | claimed |
| WO-2012017166-A2 | BENZENESULFONAMIDE-COMPOUND TREATMENT OF A PATHOLOGICAL CONDITION LINKED TO AN EXCESSIVE EFFECT OF TNF | VAXCONSULTING (FR) | 2012-02-09 | — | — | WO | claimed |
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | claimed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | claimed |
| US-8975399-B2 | Benzenesulfon amide-compound treatment of a pathological condition linked to an excessive effect of TNF | VAX-CONSULTING (FR) | 2015-03-10 | — | — | US | disclosed |
| EP-2595620-A2 | BENZENESULFONAMIDE-COMPOUND TREATMENT OF A PATHOLOGICAL CONDITION LINKED TO AN EXCESSIVE EFFECT OF TNF | Vaxconsulting (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | VAX-CONSULTING (FR) | 2013-05-16 | — | — | US | disclosed |
| WO-2012017166-A2 | BENZENESULFONAMIDE-COMPOUND TREATMENT OF A PATHOLOGICAL CONDITION LINKED TO AN EXCESSIVE EFFECT OF TNF | VAXCONSULTING (FR) | 2012-02-09 | — | — | WO | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | ALDH1A1 1549/4885GAA 601/4885F2 4560/4885 |
| US-20130123266-A1 | TREATMENT OF A PATHOLOGY LINKED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULPHONAMIDE COMPOUND | TNF, TNFRSF1A, TRAF6 | ALDH1A1 205/4885GAA 373/4885F2 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.